Ninety One North America, Inc. Abb Vie Inc. Transaction History

Ninety One North America, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 27, 2022	SELL	$131.98 - $163.75 $7.66 Million - $9.51 Million	-58,066 Closed	0 $0
Q1 2021 May 07, 2021	BUY	$102.3 - $112.62 $436,616 - $480,662	4,268 Added 7.93%	58,066 $6.28 Million
Q3 2020 Nov 12, 2020	SELL	$85.91 - $100.83 $43,556 - $51,120	-507 Reduced 0.93%	53,798 $4.71 Million
Q2 2020 Aug 20, 2020	SELL	$73.37 - $98.18 $5.05 Million - $6.75 Million	-68,794 Reduced 55.89%	54,305 $5.33 Million
Q2 2020 Aug 13, 2020	SELL	$73.37 - $98.18 $10 Million - $13.4 Million	-136,780 Reduced 52.63%	123,099 $10.9 Million
Q1 2020 May 12, 2020	BUY	$64.5 - $97.79 $8.82 Million - $13.4 Million	136,780 Added 111.11%	259,879 $19.8 Million
Q4 2019 Feb 07, 2020	BUY	$72.13 - $90.25 $8.88 Million - $11.1 Million	123,099 New	123,099 $10.9 Million

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Ninety One North America, Inc., based on Form 13F filings with the SEC.

Stay updated on Ninety One North America, Inc. with notifications on news.